hotspot -WSS

hotspot

author：focus 2025-10-02 01:08:22 - browse：8

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Judge agrees to delay next hearing in Trump classified documents case

WSS

Why doctors need education on FDA device approval process

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Dewpoint Therapeutics lays off staff after losing partnerships

Test for long Covid? Researchers find new clue in blood samples

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

Medicare Advantage today, explained in one chart

ChatGPT in medicine: STAT answers readers' burning questions

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

After affirmative action ruling, medical educators look to 'holistic review'

Biden targets hefty hospital 'facility fees' that often surprise patients

23andMe had bad news about my health. I wish a person had delivered it

Independent physicians launch a new lobbying group

How to save PrEP access — and even expand it

Prior authorization will have to move faster under new Biden rule

focus

Test for long Covid? Researchers find new clue in blood samples

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

The tragedy of Johnson & Johnson’s Covid vaccine

My yearlong odyssey to get my son’s ADHD medication covered

NIH director takes cautious approach to Biden drug pricing priority

hotspot

focus

leisure time

hotspot